Article Text

Download PDFPDF
Extended report
Fcγ receptor type IIIA polymorphism influences treatment outcomes in patients with rheumatoid arthritis treated with rituximab
  1. A Ruyssen-Witrand1,
  2. S Rouanet2,
  3. B Combe3,
  4. M Dougados4,
  5. X Le Loët5,
  6. J Sibilia6,
  7. J Tebib7,
  8. X Mariette8,
  9. A Constantin1
  1. 1Department of Rheumatology, Purpan Teaching Hospital, Toulouse, UMR U1027 INSERM, UMR 1027, Université Paul Sabatier, Toulouse III, France
  2. 2Roche, Paris, France
  3. 3Immuno-Rheumatology, Lapeyronie University Hospital, Montpellier I University, Montpellier, France
  4. 4Paris-Descartes University, UPRES-EA 4058, Rheumatology B, Cochin Hospital, France
  5. 5Department of Rheumatology, Rouen University Hospital & INSERM U905, Rouen, France
  6. 6Rheumatology, Hôpitaux Universitaires de Strasbourg, Strasbourg, France
  7. 7Rheumatology, Centre Hospitalier Lyon-Sud, Pierre-Bénite, France
  8. 8Rhumatologie, Hôpital Bicêtre, Assistance Publique-Hôpitaux de Paris, INSERM U1012, Université Paris-Sud 11, Le Kremlin Bicêtre, France
  1. Correspondence to A Ruyssen-Witrand, Centre de Rhumatologie, Hôpital Purpan, 1 place du Dr Baylac, 31059 Toulouse Cedex 09, France; adruyssen{at}


Objective To assess the association between a single nucleotide polymorphism in the gene of FCGR3A and the response to treatment with rituximab (RTX) in rheumatoid arthritis (RA).

Methods SMART is a randomised open trial assessing two strategies of re-treatment in patients responding to 1 g infusion of RTX with methotrexate on days 1 and 15 after failure, intolerance or contraindication to tumour necrosis factor (TNF) blockers. Among the 224 patients included, 111 could be genotyped and were included in an ancillary study of SMART. Univariate and multivariate analyses adjusted on disease activity score on 28 joints were performed to assess whether FCGR3A-158V/F polymorphism was associated with European League Against Rheumatism response at week 24.

Results Among the 111 patients, 90 (81%) were responders of whom 30 (27%) were good responders. V allele carriage was significantly associated with a higher response rate (91% of responders vs 70%, OR 4.6 (95% CI 1.5 to 13.6), p=0.006). These results were also confirmed in rheumatoid factor-positive patients (93% vs 74%, p=0.025). In multivariate analysis, V allele carriage was independently associated with response to RTX (OR 3.8 (95% CI 1.2 to 11.7), p=0.023).

Conclusion The 158V/F polymorphism of FCGR3A seems to influence the response to RTX in patients with RA after failure, intolerance or contraindication to TNF blockers.

Statistics from


  • Funding Roche France sponsored the study but was not involved in the interpretation of the data or in the preparation of the manuscript.

  • Competing interests The authors belonging to the scientific committee of the SMART study (ARW, BC, XLL, JT, JSi, MD, XM, AC) received honoraria from Roche (less than $10 000 each) for this study.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.